Verismo Therapeutics Company Profile, Contacts & Intelligence

Verismo Therapeutics Overview

Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.

Headquarters

3675 Market St

Website

verismotherapeutics.com

Industry

Biotechnology Research

Founded

2020

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Verismo Therapeutics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Verismo Therapeutics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Verismo Therapeutics Workforce Composition

Seniority breakdown across 4 visible profiles.

Compare Similar Companies to Verismo Therapeutics

Explore companies in related markets and compare their industry and employee estimates.